Large-Cap Healthcare Stocks Hold Gains as Market Nears Close
NEW YORK — Large-cap healthcare stocks including AstraZeneca PLC (NASDAQ:AZN), Merck & Co. (NYSE:MRK), and Pfizer (NYSE:PFE) maintained gains in late trading Tuesday, reflecting a steady appetite for pharmaceutical shares amid ongoing clinical development momentum. The sector’s resilience is underscored by AbbVie (NYSE:ABBV) and Genmab A/S (NASDAQ:GMAB) announcing significant data from their Phase 3 trial evaluating epcoritamab combined with R-CHOP chemotherapy in newly diagnosed diffuse large B-cell lymphoma (DLBCL). These developments highlight the dynamic pipeline efforts driving investor positioning even as broader market volatility persists.
The EPCORE DLBCL-2 trial showed that the combination of epcoritamab, a bispecific antibody, with the standard R-CHOP regimen reduced the risk of disease progression or death by 51% compared to R-CHOP alone in patients with intermediate to high-risk DLBCL as defined by International Prognostic Index scores of 2-5. Specifically, the hazard ratio was 0.49 (95% confidence interval 0.36-0.67, p<0.0001), indicating an improvement in progression-free survival. While overall survival data and a cure rate improvement have not been demonstrated, the results represent a meaningful advancement in frontline lymphoma treatment strategies. AbbVie and Genmab have indicated plans for regulatory discussions and further data presentations at upcoming medical congresses. Importantly, epcoritamab remains investigational and not approved for this indication at this time.
This clinical news coincides with steady gains by heavyweight pharmaceutical names, pointing to sustained capital flows into healthcare amid a macro environment where demand for innovative therapies and robust pipelines remains a key investor consideration. AstraZeneca shares rose 1.21% to $158.42, buoyed by a diversified late-stage pipeline and momentum in oncology and immunology franchises. Merck shares ticked up 1.25% to $141.28, supported by expectations around label expansions and ongoing trial readouts for immuno-oncology agents. Pfizer’s stock edged higher by 0.22% to $27.47, reflecting stable investor interest as it advances multiple vaccine candidates and specialty medicines.
| Company | Ticker | Price (USD) | Change | Investor Information |
|—————|——–|————-|———|————————————|
| AstraZeneca | AZN | 158.42 | +1.21% | https://www.astrazeneca.com/ |
| Merck | MRK | 141.28 | +1.25% | https://www.merck.com/ |
| Pfizer | PFE | 27.47 | +0.22% | https://www.pfizer.com/ |
Market data Source snapshot Yahoo Finance, October 6, 2026
AbbVie and Genmab continue to focus on advancing epcoritamab, a potential immunotherapy complementing existing treatment backbones for hematologic cancers. Their collaboration emphasizes a trend in biopharma that leverages bispecific antibodies to enhance durable responses without compromising safety, as the reported tolerability profile aligns with known effects of the individual agents. This clinical progression is instrumental for investors gauging the pipeline’s potential impact on future revenue streams, particularly as regulatory dialogues approach.
The broader healthcare sector’s ability to hold gains amid fluctuating equity markets suggests that investor sentiment remains partially anchored in innovation-led growth opportunities. While clinical milestones contribute to episodic share price movements, they also inform medium-term positioning by quantifying incremental efficacy benefits and preparing for potential regulatory milestones. At the same time, cautious optimism persists given that investigational combinations like epcoritamab plus R-CHOP are subject to further scrutiny before formal market introduction.
Looking ahead, monitoring upcoming regulatory engagements and conference disclosures will be critical for understanding whether these encouraging progression-free survival results translate into labeling updates or broader commercial adoption frameworks. For market participants, the pace of approvals and real-world uptake will shape capital allocation strategies as pharmaceutical companies balance pipeline delivery against competitive pressures and reimbursement dynamics.
Sources and further corporate investor information:
AbbVie: https://www.abbvie.com/
Genmab: https://www.genmab.com/
AstraZeneca: https://www.astrazeneca.com/
Merck: https://www.merck.com/
Pfizer: https://www.pfizer.com/
Genmab official: https://ir.genmab.com/news-releases/news-release-details/genmab-and-abbvie-announce-epcoritamab-combination-r-chop
Spotrate NewsDesk